Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 2Phase NA 1

Status

Completed 11Unknown 9Terminated 9Recruiting 7Active not recruiting 4Withdrawn 3Not yet recruiting 3Suspended 1

Sponsor Class

OTHER 25INDUSTRY 7NETWORK 1

Study Type

Interventional 7

Sponsor

Cancer Type

Thoracic 7

Conditions

Carcinoma, Non-Small-Cell Lung 429Breast Neoplasms 298Neoplasms 296Colorectal Neoplasms 242Neoplasm Metastasis 197Ovarian Neoplasms 171Lung Neoplasms 150Recurrence 147Prostatic Neoplasms 146Pancreatic Neoplasms 142Multiple Myeloma 136Stomach Neoplasms 129Squamous Cell Carcinoma of Head and Neck 128Melanoma 123Leukemia, Myeloid, Acute 115Endometrial Neoplasms 115Advanced Solid Tumors 113Advanced Solid Tumor 108Carcinoma, Hepatocellular 102Triple Negative Breast Neoplasms 101Small Cell Lung Carcinoma 88Uterine Cervical Neoplasms 86Lymphoma, Non-Hodgkin 83Carcinoma, Renal Cell 72Lymphoma, Follicular 71Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 65Solid Tumor 64Lymphoma, Large B-Cell, Diffuse 64Hematologic Neoplasms 62

Interventions

Pemetrexed 2Carboplatin 2spartalizumab 1pembrolizumab 1osimertinib 1aflutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × NSCLC × Clear all
NCT07169552 2025-12-17

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients

HC Biopharma Inc.

Phase 2 Recruiting
50 enrolled
Thoracic

NSCLC

NCT07181499 2025-09-30

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

Betta Pharmaceuticals Co., Ltd.

Phase 2 Recruiting
28 enrolled
Thoracic

NSCLC

NCT06754644 2025-06-10

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
808 enrolled
Thoracic

NSCLC

NCT06940401 2025-05-14

JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations

Suzhou Junjing BioSciences Co., Ltd.

Phase 1/2 Recruiting
42 enrolled
Thoracic

NSCLC

NCT05994131 2025-04-30

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
110 enrolled
Thoracic

NSCLC

NCT05987345 2024-07-22

Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer

Energenx Medical LTD.

Phase NA Recruiting
10 enrolled
Thoracic

NSCLC

NCT05382728 2024-01-30

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

TYK Medicines, Inc

Phase 3 Recruiting
680 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡